Cardiac macrophages found to contribute to a currently untreatable type of heart failure

February 14, 2018, Massachusetts General Hospital
Credit: CC0 Public Domain

A team of Massachusetts General Hospital (MGH) investigators has discovered, for the first time, that the immune cells called macrophages contribute to a type of heart failure for which there currently is no effective treatment. In their report published in the February issue of the Journal of Experimental Medicine, the MGH team describes finding how macrophage activity leads to the development of heart failure with preserved ejection fraction (HFpEF) in mouse models of the condition, which accounts for around half of all human heart failure cases.

"We show that macrophages - primarily known for removing cellular debris, pathogens and other unwanted materials - are actively involved in the development of HFpEF," says Maarten Hulsmans, PhD, a research fellow in the MGH Center for Systems Biology and lead author of the paper. "These findings put macrophages on the map when it comes to HFpEF therapy and open up previously unexplored treatment options."

The concept of heart failure traditionally referred to a loss of the organ's pumping capacity, which is called . But in HFpEF the heart retains the ability to pump or eject blood into the circulation. What is compromised is the ability of the heart muscle to relax and allow blood to flow into the left ventricle, reducing the amount of blood available to pump into the aorta. Symptoms of HFpEF are similar to those of in general, but since factors contributing to the condition are not well understood, it has been difficult to find promising therapies.

Interactions among cells within the heart - including macrophages - are essential to normal but can also contribute to problems. For example, after the heart muscle is damaged by a heart attack, macrophages induce the cells called fibroblasts to generate the connective tissues that help reinforce damaged tissue. But excessive fibroblast activation can lead to the distortion and stiffening of tissues, further reducing cardiac function.

To explore a potential role for macrophages in HFpEF, the MGH team examined cardiac macrophages in two mouse models that develop the sort of diastolic dysfunction - impaired relaxation of the - that characterizes HFpEF. Those animals were found to have increased macrophage density in the and exhibited elevated levels of a factor called IL-10, which is known to contribute to fibroblast activation. Deletion of IL-10 from cardiac macrophages in one model, in which the development of hypertension is induced, prevented the upregulation of macrophages and reduced the numbers and activation of cardiac fibroblasts. Levels of cardiac macrophages were also elevated in tissue biopsies from human patients with HFpEF, as were levels of circulating monocytes, which are precursors of macrophages.

"Not only were numbers of inflammatory cardiac macrophages increased in both the mice and in humans with HFpEF, but their characteristics and functions were also different from those in a healthy heart," says Hulsmans. "Through their participation in the remodeling of tissue, these macrophages increase the production of extracellular matrix, which reduces diastolic relaxation. Our findings regarding the cell-specific knockout of IL-10 are the first to support the contribution of macrophages to HFpEF."

Senior author Mathias Nahrendorf, MD, PhD , of the Center for Systems Biology, adds, "Heart muscle cells and fibroblasts have been considered the major contributors to HFpEF. Our identification of the central involvement of macrophages should give us a new focus for drug development. And since naturally take up materials for disposal, inducing them to ingest drugs carried in by nanoparticles could limit their contributions to the development of HFpEF." Nahrendorf is a professor of Radiology at Harvard Medical School.

Explore further: Researchers identify potential treatment for diastolic dysfunction in heart failure

More information: Maarten Hulsmans et al, Cardiac macrophages promote diastolic dysfunction, The Journal of Experimental Medicine (2018). DOI: 10.1084/jem.20171274

Related Stories

Researchers identify potential treatment for diastolic dysfunction in heart failure

February 7, 2018
Researchers at the University of Colorado School of Medicine have identified a potential treatment target for patients with a common type of heart failure.

Macrophages shown to be essential to a healthy heart rhythm

April 20, 2017
A Massachusetts General Hospital (MGH)-led research team has identified a surprising new role for macrophages, the white blood cells primarily known for removing pathogens, cellular debris and other unwanted materials. In ...

Abdominal obesity linked to all-cause mortality in HFpEF

November 28, 2017
(HealthDay)—For patients with heart failure with preserved ejection fraction (HFpEF), abdominal obesity is associated with increased risk of all-cause mortality, according to a study published in the Dec. 5 issue of the ...

Macrophage population activates repair in murine heart attack model

May 3, 2016
Following a heart attack, successful repair of damaged tissue can prevent cardiac rupture and other adverse outcomes. The ability to repair myocardial tissue depends on the activation of fibroblasts, which stimulate the formation ...

Ivabradine may not benefit certain heart failure patients

April 30, 2017
Researchers have completed a randomized clinical trial in patients with heart failure with preserved ejection fraction (HFpEF), which currently has no effective treatment for reducing morbidity and mortality.

Altering the appearance of macrophages to prevent atherosclerosis

February 8, 2018
It might be possible to prevent atherosclerosis by changing the appearance of macrophages, cells of the immune system that for example digest foreign substances. In her Ph.D. dissertation, Baoyan Ren examined several ways ...

Recommended for you

No sweat required: Team finds hypertension treatment that mimics effect of exercise

October 16, 2018
Couch potatoes rejoice—there might be a way to get the blood pressure lowering benefits of exercise in pill form.

New model suggests cuffless, non-invasive blood pressure monitoring possible using pulse waves

October 16, 2018
A large team of researchers from several institutions in China and the U.S. has developed a model that suggests it should be possible to create a cuffless, non-invasive blood pressure monitor based on measuring pulse waves. ...

Why heart contractions are weaker in those with hypertrophic cardiomyopathy

October 16, 2018
When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and affects an estimated 1 in 500 ...

Novel genetic study sheds new light on risk of heart attack

October 12, 2018
Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife.

Researchers say ritual for orthodox Jewish men may offer heart benefits

October 11, 2018
A pilot study led by researchers at the University of Cincinnati (UC) College of Medicine suggests Jewish men who practice wearing tefillin, which involves the tight wrapping of an arm with leather banding as part of daily ...

Markers of dairy fat consumption linked to lower risk of type two diabetes

October 10, 2018
Higher levels of biomarkers of dairy fat consumption are associated with a lower risk of developing type 2 diabetes, according to new research published today in PLOS Medicine. The study, in more than 60,000 adults, was undertaken ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.